相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis.
U. Gürtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
Aurora Kinase inhibitors: Current Status and Outlook
Vassilios Bavetsias et al.
FRONTIERS IN ONCOLOGY (2015)
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
P. Schoffski et al.
ANNALS OF ONCOLOGY (2015)
A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
Christian Dittrich et al.
INVESTIGATIONAL NEW DRUGS (2015)
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
Hielke J. Meulenbeld et al.
BJU INTERNATIONAL (2013)
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
Hagop M. Kantarjian et al.
CANCER (2013)
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
Gary K. Schwartz et al.
INVESTIGATIONAL NEW DRUGS (2013)
Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle
Helfrid Hochegger et al.
OPEN BIOLOGY (2013)
Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
Andres Cervantes et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
E. Claire Dees et al.
CLINICAL CANCER RESEARCH (2012)
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Ursula A. Matulonis et al.
GYNECOLOGIC ONCOLOGY (2012)
Aurora kinase inhibitors: Progress towards the clinic
Madhu Kollareddy et al.
INVESTIGATIONAL NEW DRUGS (2012)
Mitosis-targeted anti-cancer therapies: where they stand
K-S Chan et al.
CELL DEATH & DISEASE (2012)
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
D. S. Boss et al.
ANNALS OF ONCOLOGY (2011)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
Bob Lowenberg et al.
BLOOD (2011)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Feedback Control in Sensing Chromosome Biorientation by the Aurora B Kinase
Kevan J. Salimian et al.
CURRENT BIOLOGY (2011)
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2011)
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
Kosuke Tsuboi et al.
LEUKEMIA RESEARCH (2011)
Sensing centromere tension: Aurora B and the regulation of kinetochore function
Michael A. Lampson et al.
TRENDS IN CELL BIOLOGY (2011)
Molecular and cellular pharmacology of BI 811283, a potent inhibitor of Aurora B kinase
Ulrike Tontsch-Grunt et al.
CANCER RESEARCH (2010)
BI 811283, a potent inhibitor of the mitotic kinase Aurora B, shows dose- and schedule-dependent efficacy in human cancer xenograft models
Ulrich Gurtler et al.
CANCER RESEARCH (2010)
Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
Teresa Macarulla et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Microtubule Active Agents: Beyond the Taxane Frontier
Patrick G. Morris et al.
CLINICAL CANCER RESEARCH (2008)
Aurora kinases as anticancer drug targets
Oliver Gautschi et al.
CLINICAL CANCER RESEARCH (2008)
Aurora kinases A and B and familial breast cancer risk
Sandrine Tchatchou et al.
CANCER LETTERS (2007)
Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme
Weifen F. Zeng et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients
Barbara Vischioni et al.
MOLECULAR CANCER THERAPEUTICS (2006)
PHA-680632, a novel aurora kinase inhibitor with potent antitumoral activity
Chiara Soncini et al.
CLINICAL CANCER RESEARCH (2006)
Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation
P Chieffi et al.
PROSTATE (2006)
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability
SL Smith et al.
BRITISH JOURNAL OF CANCER (2005)
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation
R Sorrentino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
High expression of Aurora-B/Aurora and Ipl1-like midbody-associated protein (AIM-1) in astrocytomas
K Araki et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker
S Linder et al.
CANCER LETTERS (2004)
The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint
S Hauf et al.
JOURNAL OF CELL BIOLOGY (2003)
The budding yeast Ipl1/Aurora protein kinase regulates mitotic spindle disassembly
S Buvelot et al.
JOURNAL OF CELL BIOLOGY (2003)
Cohesin release is required for sister chromatid resolution, but not for condensin-mediated compaction, at the onset of mitosis
A Losada et al.
GENES & DEVELOPMENT (2002)
Evidence that the Ipl1-Sli15 (Aurora knase-INCENP) complex by altering promotes chromosome bi-orientation kinetochore-spindle pole connections
TU Tanaka et al.
CELL (2002)
Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian aurora kinases
C Crosio et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Role of chromosomal passenger complex in chromosome segregation and cytokinesis
Y Terada
CELL STRUCTURE AND FUNCTION (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow
RR Adams et al.
CURRENT BIOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
